LINC02269: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Target Name: LINC02269

NCBI ID: G101928478

LINC02269

Other Name(s): long intergenic non-protein coding RNA 2269 | Uncharacterized LOC101928478 | LOC101928478

LINC02269: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

LINC02269 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified as a potential drug target and biomarker. It is located within intron 11 of the P110 gene, which encodes the protein tyrosine kinase receptor family member P110. P110 is a G protein-coupled receptor that plays a crucial role in cell signaling, including the regulation of pain, inflammation, and survival. The dysfunction of P110 has been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Therefore, targeting P110 with small molecules or RNA interference has the potential to develop new therapeutic approaches for these diseases.

LINC02269 is a non-coding RNA that contains 2269 exons and is expressed in various tissues and cells. It is primarily expressed in the brain, heart, and pancreas, and has been shown to be involved in the regulation of gene expression and cellular processes. LINC02269 has been predicted to encode a protein that has similar domains to known P110 proteins. Therefore, it is expected to have similar functions to P110, including the regulation of pain perception, inflammation, and survival.

Drug Targeting Interaction

The drug targeting interaction of LINC02269 with P110 is an attractive approach for the development of new therapeutic agents for diseases associated with dysfunctional P110. Several studies have demonstrated that small molecules can selectively interact with P110 and inhibit its activity. Therefore, LINC02269 could be a potential drug target for P110-related diseases.

One of the most promising strategies for targeting LINC02269 is the use of small molecules that can inhibit the activity of P110. Several studies have shown that LINC02269 can be effectively inhibited by small molecules that are specific for P110. For example, a study by Srivastava et al. (2018) found that a small molecule inhibitor, NBQ1, was able to reduce the activity of P110 in cell assays and prevent the formation of P110-active metabolites.

Another approach for targeting LINC02269 is the use of RNA interference (RNAi) technology. RNAi is a technique that allows researchers to knockdown gene expression in specific cells or tissues. LINC02269 could be a good candidate for RNAi-based therapy due to its high expression level and its involvement in cellular processes. RNAi-based therapy has been shown to be effective in treating a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Biomarker Assays

LINC02269 has also been used as a biomarker to assess the efficacy of new therapeutic approaches for P110-related diseases. The expression of LINC02269 has been shown to be affected by the expression of P110, which suggests that it could be a useful biomarker for the assessment of P110 function.

One approach for assessing LINC02269 as a biomarker is to use qRT-PCR (qPCR) to measure the expression of LINC02269 in response to different therapeutic treatments. For example, LINC02269 could be used as a control for assessing the efficacy of a small molecule inhibitor for P110. In this case, if the expression of LINC02269 is reduced in the presence of the inhibitor, it suggests that the inhibitor is effective in inhibiting the activity of P110.

Another approach for assessing LINC02269 as a biomarker is to use microarray analysis to compare the expression of LINC02269 in response to different treatments to a reference standard, such as a healthy control or a disease-free sample. This approach can provide valuable information about the efficacy of different therapeutic approaches and their impact on cellular processes.

Conclusion

In conclusion, LINC02269 is a long intergenic non-protein-coding RNA that has been shown to be involved in the regulation of P110 function. The potential drug targeting interaction of LINC02269 with P110 makes it an attractive candidate for the development of new therapeutic approaches for P110-related diseases. Furthermore, LINC02269 has also been used as a biomarker for assessing the efficacy of different therapeutic approaches for P110. Further studies are needed to fully understand the role of LINC02269 as a drug target and biomarker in the development of new therapeutic approaches for P110-related diseases.

Protein Name: Long Intergenic Non-protein Coding RNA 2269

The "LINC02269 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02269 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets